Your session is about to expire
← Back to Search
AU-007 for Advanced Cancer
Study Summary
This trial is testing a new drug, AU-007, to see if it is safe and effective in treating people with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am experiencing hair loss.I haven't taken more than 10 mg of prednisone or similar drugs in the last week.I have had an ongoing inflammation for more than 4 weeks.My brain metastases have been treated and I've had no symptoms for over 14 days.I still have side effects from previous cancer treatments.I have a skin condition like psoriasis but don't need strong medication for it.I have had another cancer, but it's been in remission for over a year, or it was a minor type that didn't need treatment.I have wounds from surgery or injury that have not healed.I have had cancer treatment before starting AU-007.I am a male and will use contraception, and ensure my partner does too, while on AU-007 and for 60 days after.I have not had major surgery or serious injuries in the last 8 weeks.My arthritis is managed with just over-the-counter pain meds.My cancer can be measured or seen on scans.I am still experiencing side effects from my recent radiotherapy.I have had severe side effects from IL-2 therapy, such as heart issues or bleeding.My cancer has worsened after standard treatment, or I cannot tolerate or refused it.I had immune therapy side effects, but they're mostly gone or treated, except for thyroid issues which are under control.I am using hormones for prostate cancer or other conditions, and may be taking bisphosphonates.I do not have cancer spread to the lining of my brain or spinal cord.I am not pregnant and agree to use two forms of birth control or practice abstinence during the study.I had Graves' disease but have been stable without symptoms for over 4 weeks.I have vitiligo.I am not currently receiving treatment for brain disease.My underactive thyroid is treated with hormone replacement.
- Group 1: AU-007 Monotherapy
- Group 2: AU-007 combined with an aldesleukin loading dose
- Group 3: AU-007 combined with aldesleukin given concomitantly
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment for this research project currently available to participants?
"As evidenced by the clinicaltrials.gov listing, this research endeavour is actively enrolling participants. The study was initially posted on April 4th 2022 and recently updated on November 28th 2022."
How many locations have been identified for the execution of this trial?
"Four medical institutions are currently enrolling patients in this trial, including Tennessee Oncology in Nashville, START South Texas Accelerated Research Therapeutics in Grand Rapids and Carolina Biooncology Institute. Additionally, there is representation from other locations as well."
What is the recruitment number of participants for this trial?
"To ensure that the trial is adequately powered, Aulos Bioscience Inc. requires 69 participants who meet the criteria for inclusion. Enrollment will take place across two sites: Tennessee Oncology in Nashville and START South Texas Accelerated Research Therapeutics situated in Grand Rapids."
Share this study with friends
Copy Link
Messenger